Audentes is enrolling patients in the phase 1/2 clinical trial to evaluate their investigational gene therapy product candidate in participants who are 18 years of age or older, ambulatory or non-ambulatory, with late-onset Pompe disease (LOPD). Updates have been made to the FORTIS page on clinicaltrials.gov. Clinical trial sites actively recruiting are listed.
Read more
- Program update (PDF, 254 KB)
Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.